TARRYTOWN, N.Y. (May 9, 2008) EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today announced that on May 7, 2008 it was notified by the Nasdaq Listing Qualifications Department that EpiCept has not regained compliance with the continued listing requirements of The Nasdaq Capital Market because the market value of EpiCepts listed securities fell below $35,000,000 for ten consecutive trading days (pursuant to Rule 4310(c)(3)(B) of the Nasdaq Marketplace Rules). As a result, its securities are subject to delisting from The Nasdaq Capital Market.

TARRYTOWN, N.Y. (April 18, 2008) EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today announced that it has received a letter from the Nasdaq Listings Qualification Department stating that EpiCept is not in compliance with the continued listing requirements...

TARRYTOWN, N.Y. (April 7, 2008) EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today announced that it has received a letter from the Nasdaq Listings Qualification Department...

TARRYTOWN, N.Y. (April 8, 2008) EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today announced that it will present new drug discovery advances emanating from its Anti-cancer Screening Apoptosis Platform (ASAP) ...

TARRYTOWN, N.Y. (April 7, 2008) EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today released clinical study results from the Phase I trial of EPC2407, which provided visible evidence of vascular disruptive activity.